The impact of opioid substitution therapy on mortality post-release from prison: Retrospective data linkage study

 

 

Louisa Degenhardt PhD, Sarah Larney PhD, Jo Kimber PhD, Natasa Gisev PhD, Michael Farrell PhD, Timothy Dobbins PhD, Don J. Weatherburn PhD, Amy Gibson PhD, Richard Mattick PhD, Tony Butler PhD, Lucy Burns

Addiction March 2014, DOI: 10.1111/add.12536

 

http://onlinelibrary.wiley.com/doi/10.1111/add.12536/abstract

 

Abstract

Aims

Release from prison is a high-risk period for mortality. We examined the impact of opioid substitution therapy (OST), for opioid dependence during and after incarceration, upon mortality post-release.

Design

A cohort was formed of all opioid dependent people who entered OST between 1985 and 2010, and who, following first OST entry, were released from prison at least once between 2000 and 2012. We linked data on OST history, court and prison records, and deaths.

Setting

New South Wales (NSW), Australia.

Participants

N=16,453 people released from prison N=60,161 times.

Measurements

Crude mortality rates (CMRs) were calculated according to OST retention; multivariable Cox regressions for post-release periods were undertaken to examine the association between OST exposure (a time dependent variable) and mortality post-release, for which covariates were updated per-release.

Findings

There were 100,978 person-years (PY) post-release; 1,050 deaths occurred. Most received OST while incarcerated (76.5%); individuals were receiving OST in 51% of releases. Lowest post-release mortality was among those continuously retained in OST post-release (CMR 4-weeks post-release: 6.4 per 1,000PY; 95% CI: 5.2, 7.8), highest among those with no OST (CMR: 36.7 per 1,000PY; 95% CI: 28.8, 45.9). Multifactorial models showed OST exposure in the four weeks post-release reduced hazard of death by 75% (adjusted hazard ratio 0.25; 95%CI: 0.15, 0.52); OST receipt in prison had a short-term protective effect that decayed quickly across time.

Conclusion

In New South Wales, Australia, opioid substitution therapy in prison and post-release appears to reduce mortality risk in the immediate post-release period.